

# TURCAN, SEVIN, PH.D

## GENERAL INFORMATION



**Junior Research Group Leader**  
Heidelberg University Hospital, Department of Neurology  
Im Neuenheimer Feld 460  
69120 Heidelberg, Germany

A04

## ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2004-2010	PhD, Biomedical Engineering, Tufts University
2002-2004	Master of Science, Biomedical Engineering, Tufts University
1998-2002	Bachelor of Science, Biomedical Engineering, Johns Hopkins University

## SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2004-2010	PhD, Biomedical Engineering, Tufts University Dissertation: Computational approaches to studying peripheral auditory system development and protection against ototoxicity Mentor: Douglas Vetter

## PROFESSIONAL EXPERIENCE

Year(s)	Experience
2016 – Present	Max-Eder junior research group leader, Department of Neurology Heidelberg University Hospital
2010-2016	Postdoctoral fellow, Memorial Sloan Kettering Cancer Center

## OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2018	Hella Bühler Award
2016	Max-Eder-Nachwuchsgruppe, Deutsche Krebshilfe
2016-2017	The Imaging and Radiation Sciences Program (IMRAS) Memorial Sloan Kettering Cancer Center
2015-2016	B*CURED award (Co-investigator, PI: Carl LeKaye)
2016-2018	Starr Cancer Consortium Grant (Investigator, PI: Je Lee)
2012-2014	NIH NRSA Postdoctoral Institutional Training Grant
2013	Memorial Sloan-Kettering Cancer Center Postdoctoral Researcher Award
2011	Travel Award, Pacific Symposium on Biocomputing (Invited Speaker), Hawaii, HI
2008	Travel Award, Association for Research in Otolaryngology, Phoenix, Arizona

## SELECTED PUBLICATIONS

- [Turcan S](#), Makarov V, Taranda J, Wang Y, El-Amine N, Haddock S, Nanjangud G, LeKaye CH, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA. **Nat Genet** 2018;50(1):62-72
- Bai H, Harmanci AS, Erson-Omay EZ, Li J, Simon M, Krischek B, Ozduman K, Coskun S, Omay SB, Sorensen EA, [Turcan S](#), Bakircioglu M, Carrion-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Timmer M, Schramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, Chan TA, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, Gunel M. Integrated Genomic Characterization of IDH1 mutant glioma malignant progression. **Nat Genet** 2016;48(1):59-66

3. Reyngold M, [Turcan S](#), Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, Chan TA. Remodeling of the methylation landscape in breast cancer metastasis. **PLoS One** 2014;9(8):e103896
4. Gerber NK, Goenka A, [Turcan S](#), Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. **Neuro Oncol** 2014;16(9):1186-95
5. [Turcan S](#), Fabius AWM, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, and Chan TA, Efficient Induction of Differentiation and Growth Inhibition in IDH1 Mutant Glioma Cells by the DNMT Inhibitor Decitabine. **Oncotarget** 2013;4(10):1729-36
6. Rohle D, Popovici-Muller J, Palaskas N, [Turcan S](#), Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. **Science** 2013;340(6132):626-30
7. [Turcan S](#), Rohle D, Goenka A, Walsh L, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LGT, Huse JT, Mellinghoff I, Chan TA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. **Nature** 2012;483(7390):474-8
8. Lu C, Ward PS, Kapoor GS, Rohle D, [Turcan S](#), Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. **Nature** 2012;483(7390):474-8
9. Fang F, [Turcan S](#), Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA. Breast cancer methylomes establish an epigenomic foundation for metastasis. **Sci Transl Med** 2011;3(75):75ra25
10. [Turcan S](#), Slonim DK, Vetter DE. Lack of nAChR activity depresses cochlear maturation and up-regulates GABA system components: temporal profiling of gene expression in alpha9 null mice. **PLoS One** 2010;5(2):e9058

## PATENTS

- Timothy A. Chan, Fang Fang, Sevin Turcan. Epigenomic markers of cancer metastasis (US20140113286)